Nottingham biosciences million pound injectionJuly 30, 2007Nottingham's strength as a UK Science City is further underlined today, with news that the Wellcome Trust, the UK's largest medical research charity, has awarded almost £1 million to an innovative biosciences company. The investment, under the Translation Award programme, will help Nottingham-based RegenTec Ltd to develop commercial products in the rapidly-developing field of regenerative medicine. The company has perfected techniques which could greatly enhance the repair of bone defects and fractures. RegenTec Ltd was created to build on the world-changing research carried out by scientists at The University of Nottingham, Britain's 'University of the Year'. With support from the East Midlands Development Agency, the company has invented a unique material that works with stem cells and biopharmaceuticals to stimulate the regeneration of tissue in patients. When injected into the body the material forms a highly porous scaffold structure, which encourages new tissues to form. The unique scaffold mechanism also assists the delivery of stem cells and drugs without compromising their effectiveness. This offers a substantial opportunity to deliver a cure to patients with bone, liver, heart or nerve tissue defects. Professor Kevin Shakesheff, Chief Scientific Officer at RegenTec, and Director of The Centre for Biomolecular Sciences at The University of Nottingham, said: "The ability to inject these scaffold materials could significantly reduce the need for invasive surgery in tissue repair. "It will mean that operation and rehabilitation times could come down significantly. After injection, the porous material we use gradually degrades, leaving behind only newly formed bone tissue." RegenTec has developed an extensive portfolio of patents and hopes that its injectable technology can reach clinics within three years. Its first product - Injectabone - will be used as a replacement for bone grafting, which can be beset by problems which include a short supply of host bone, chronic post-operative pain, and an increased risk of infection. Injectabone will be launched in the US and European markets for use by orthopaedic surgeons. The material will then be adapted to help in treatment of many other diseases. Dr Robin Quirk, Managing Director, said: "Regenerative medicine is a hugely exciting worldwide industry that promises to radically improve many aspects of clinical practice. We have a world-first technology that has a remarkable range of future uses. "The Wellcome Trust Award is a substantial step forward in ensuring that the UK plays a major role in the commercial and clinical development of regenerative medicine." Dr Susan Huxtable, Director of Intellectual Property and Commercialisation at The University of Nottingham, said: "The Wellcome Trust Award is recognition of the hard work and creativity of a large team of scientists who have worked at the University of Nottingham and within Regentec over the past five years. "They are pioneers in terms of their science, but also in ensuring that the expertise and knowledge honed in a research-intensive university can be translated into commercial enterprise, and make a dynamic contribution to well-being and economic growth. We have enjoyed a record year in attracting third party investment to our portfolio of spin-out companies." The University of Nottingham |
|||||||||||||||||||||
| Related Stem Cells Current Events and Stem Cells News Articles First use of antibody and stem cell transplantation to successfully treat advanced leukemia For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options. Magnetic nanoparticles to simultaneously diagnose, monitor and treat Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve channels and induce nerve-led behaviour (such as the life-dependant thumping of our hearts), mNPs have come a long way in the past decade. Of mice and men: Stem cells and ethical uncertainties The recent creation of live mice from induced pluripotent stem cells (iPSCs) not only represents a remarkable scientific achievement, but also raises important issues, according to bioethicists at The Johns Hopkins University's Berman Institute of Bioethics. NIH-funded researchers transform embryonic stem cells into human germ cells Researchers funded in part by the National Institutes of Health have discovered how to transform human embryonic stem cells into germ cells, the embryonic cells that ultimately give rise to sperm and eggs. Stem cell therapy may offer hope for acute lung injury Researchers at the University of Illinois at Chicago College of Medicine have shown that adult stem cells from bone marrow can prevent acute lung injury in a mouse model of the disease. Placental precursor stem cells require testosterone-free environment to survive Trophoblast stem cells (TSCs), cells found in the layer of peripheral embryonic stem cells from which the placenta is formed, are thought to exhibit "immune privilege" that aids cell survivability and is potentially beneficial for cell and gene therapies. Endocrine Society calls for expanded scope and funding for stem cell research Stem cell research holds great promise for the treatment of millions of Americans with debilitating and possibly fatal diseases. Experimental treatments restore partial vision to blind people Two experimental treatments, a retinal prosthesis and fetal tissue transplant, restored some vision to people with blinding eye diseases. The findings, presented at Neuroscience 2009, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health, may lead to new treatments for the blind. Scientists demonstrate link between genetic defect and brain changes in schizophrenia Researchers at the University of North Carolina at Chapel Hill School of Medicine have found that the 22q11 gene deletion - a mutation that confers the highest known genetic risk for schizophrenia - is associated with changes in the development of the brain that ultimately affect how its circuit elements are assembled. Small mechanical forces have big impact on embryonic stem cells Applying a small mechanical force to embryonic stem cells could be a new way of coaxing them into a specific direction of differentiation, researchers at the University of Illinois report. Applications for force-directed cell differentiation include therapeutic cloning and regenerative medicine. More Stem Cells Current Events and Stem Cells News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||